<DOC>
	<DOC>NCT00689780</DOC>
	<brief_summary>A Phase I, Multi-Centre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940, Including an Interaction Study, After Administration of Oral Multiple Ascending Doses in Adult Subjects with Chronic Low Back Pain</brief_summary>
	<brief_title>Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>A diagnosis of Chronic Low Back Pain according to Quebec Task force Class 13 and an average pain intensity score of 39 on NRS(010) during the past week. Clinical normal physical findings, including blood pressure, pulse rate &gt; 45bpm, ECG (with normal QTcF interval &lt;450msec and without any additional risk factors for Torsades de Pointes) and laboratory assessments, as judged by investigator Body Mass Index (BMI) ≥18 to ≤32 kg/m2 inclusive and body weight ≥50 to ≤100 kg History of somatic disease/condition which may interfere with the objectives of the study, with the exception of Chronic Low Back Pain History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder Clinically significant illness with the exception of Chronic Low Back Pain</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Pain</keyword>
	<keyword>safety</keyword>
	<keyword>chronic low back pain</keyword>
</DOC>